Research

Development of Novel Polymeric Drug and Gene Carriers

Dr. Janát-Amsbury is an Associate Professor in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology with adjunct appointments as professor in Pharmaceutics and Pharmaceutical Chemistry and Bioengineering. Dr. Janát-Amsbury currently serves as the Research Director for the Division of Gynecologic Oncology at the University of Utah. She is also a member of the Huntsman Cancer Institutes’ (HCI) Women Disease Oriented Research Team (WDOT), for which she chairs the Research Tissue Committee. Furthermore, she is a member of HCI’s Experimental Therapeutics Program (ET) Program and actively involved with the Center for Nano-Medicine at the Nano Institute of Utah. Her laboratory focuses on the generation of disease models that faithfully recapitulate the human scenario, including the development of patient-derived xenograft (PDX) models for gynecologic cancers, as well as immune-competent mouse models allowing to study effects of anticancer treatments on the immune system. These models are then utilized to develop new drug delivery and bioengineering technologies and test novel therapeutics and diagnostic tools. With the help of these models it is expected to yield more predictable information helpful to more rapidly advance new cancer treatments to clinical testing and the patient. Dr. Janát-Amsbury already guided several novel therapeutics and devices from bench to bedside, including an intraperitoneal IL-12 polymeric drug delivery system, which completed a nationwide Phase II clinical trial for the treatment of recurrent ovarian cancer (GOG-170Q). Her main missions defining her appointment with the department of obstetrics and gynecology have been to foster new collaborations to expand her cancer-focused “Translational Women’s Health Research Program”. To achieve the aforementioned goals, she founded her multidisciplinary laboratory in 2007 to work in the key areas of generating more predictive disease models for gynecologic malignancies, and developing innovative bench-to-bedside strategies for vaginal and intraperitoneal drug delivery technologies. Her labs philosophy of Collaboration, Communication, Compassion, Truthfullness and Transparency guide each team member to be the best collaborators they can be, complimenting research projects, facilitating partnerships across campus as well as other academic institutions and industry to translate novel findings efficiently to the clinic being part of the needed change in care for women battling a cancer diagnoses.